Rhovac wants to raise more than a million dollars on the stock exchange

The listed Danish company Rhovac issues new shares for up to USD 3 million, which will finance new research activities as well as speed up the company's search for a potential buyer for its cancer vaccine.

Foto: /ritzau Scanpix/Jens Panduro

Danish biotech company Rhovac has announced that it will concentrate on selling parts of, or all of the business in 2018. Paradoxically, that involves planning for the future.

Therefore, the company is already looking at new clinical trials for the company's immunotherapeutic vaccine RV001, which was recently tested in a clinical phase 1/2 study on 22 Danish prostate cancer patients.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch


Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier